[Prospective: How will renal, prostatic and urothelial tumours be treated in 10 years?]

Autor: Toledano A; Institut de cancérologie Hartmann, centre de radiothérapie Hartmann, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France; Institut Rafael, centre de médecine prédictive, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France. Electronic address: Alain.toledano@gmail.com., Bourmech M; Institut de cancérologie Hartmann, centre de radiothérapie Hartmann, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France., Lamallem H; Institut de cancérologie Hartmann, centre de radiothérapie Hartmann, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France; Institut Rafael, centre de médecine prédictive, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France., Bollet M; Institut de cancérologie Hartmann, centre de radiothérapie Hartmann, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France; Institut Rafael, centre de médecine prédictive, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France., Bauduceau O; Institut de cancérologie Hartmann, centre de radiothérapie Hartmann, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France; Institut Rafael, centre de médecine prédictive, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France., Pujol P; Institut de cancérologie Hartmann, centre de radiothérapie Hartmann, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France; Institut Rafael, centre de médecine prédictive, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France; Département d'oncogénétique, hôpital Arnaud-de-Villeneuve, 371, avenue du Doyen-Gaston-Giraud, 34295 Montpellier cedex 5, France., Bloch P; Institut Rafael, centre de médecine prédictive, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France., Khayat D; Institut de cancérologie Hartmann, centre de radiothérapie Hartmann, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France; Institut Rafael, centre de médecine prédictive, 4, rue Kléber, CS 90004, 92309 Levallois-Perret cedex, France.
Jazyk: francouzština
Zdroj: Nephrologie & therapeutique [Nephrol Ther] 2017 Apr; Vol. 13 Suppl 1, pp. S115-S125.
DOI: 10.1016/j.nephro.2017.01.013
Abstrakt: Forward thinking does not seek to predict the future, to unveil it as if it were already in existence, rather, its aim is to help us to construct it. Although today's epidemiological and therapeutic situations for urogenital tumours can evolve over the next 10 years, diagnostic and therapeutic methods, as well as the treatment and implementation of innovations, are already rapidly changing. Rather than reducing our prospective thinking to the therapeutic treatment of cancer only, we will aim at proposing a global sanitary vision that includes diagnosis, therapies, prevention, routine utilisation of technomedicine, genomics and even nanomedicine. This journey into the near future of tomorrow's cancerology holds the promise of being better adapted to the evolution of the medical thinking process. Imagining the way we will be treating renal, prostatic and urothelial tumours in 10 years' time is as much an introspection into our present day treatment system as a projection into its hoped for future evolution.
(Copyright © 2017 Société francophone de néphrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: